Can Kadcyla give Roche a softer landing when Herceptin biosims hit? New data could help

[cafead]

via Roche’s Kadcyla needs some oomph, and the Swiss drugmaker’s new data might just do the trick. The company is teeing up a new filing for its next-generation breast cancer drug, hoping to gin up more sales as its ancestor, Herceptin, moves ever closer to biosimilar competition in the U.S.

article source